Formulation and in Vitro Evaluation of Imiquimod-Loaded Zinc Oxide–Mesoporous Silica Hybrid Nanoparticles for Skin Cancer Therapy
International Journal of Drug Delivery Technology · 25.05.2026 · 16 (32s)
DOI: 10.25258/ijddt.16.32s.7 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 25.05.2026. Verfasst von Shubham Solankia und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Basal cell carcinoma represents the most common type of non-melanoma skin cancer, frequently addressed with topical immunomodulators like Imiquimod. Nonetheless, traditional topical formulations frequently encounter challenges such as inadequate skin penetration, rapid drug release, and significant local irritation, which can hinder patient adherence and overall therapeutic effectiveness.
Methods
This study focused on the development and assessment of Imiquimod-loaded zinc oxide functionalized mesoporous silica nanoparticles as an innovative topical nanocarrier system for enhanced management of Basal cell carcinoma. Mesoporous silica nanoparticles were created through a surfactanttemplated sol–gel approach and later modified with zinc oxide to improve drug affinity and provide extra dermatological advantages. Imiquimod was incorporated utilizing a solvent adsorption method, and the optimized zinc oxide-mesoporous silica nanoparticles were integrated into a biocompatible topical gel.
Results
The characterization of the formulation included assessments of particle size, drug entrapment efficiency, loading capacity, and in-vitro release behavior, all conducted using a validated high performance liquid chromatography. The safety of the formulation was evaluated through the assessment of cytotoxicity in B16-F10 melanoma cells. Zinc oxide-mesoporous silica nanoparticles exhibited a notably enhanced drug entrapment rate of approximately 94% and a sustained diffusion-controlled release, surpassing that of plain mesoporous silica nanoparticles. The topical gel demonstrated a controlled drug release for up to 72 hours and showed reduced cytotoxicity compared to free Imiquimod, suggesting enhanced tolerability. The release kinetics adhered to the Higuchi diffusion model, validating the transport of the drug through a porous matrix.
Conclusion
The developed zinc oxide-mesoporous silica nanoparticles-based gel presents a compelling approach for improving the safety, efficacy, and patient acceptability of topical Imiquimod therapy in the treatment of basal cell carcinoma.
Zitieren
APA
Solankia, S., Kulkarnib, M., & Atarac, S. (2026). Formulation and in Vitro Evaluation of Imiquimod-Loaded Zinc Oxide–Mesoporous Silica Hybrid Nanoparticles for Skin Cancer Therapy. International Journal of Drug Delivery Technology, 16(32s). https://doi.org/10.25258/ijddt.16.32s.7
Vancouver
Solankia S, Kulkarnib M, Atarac S. Formulation and in Vitro Evaluation of Imiquimod-Loaded Zinc Oxide–Mesoporous Silica Hybrid Nanoparticles for Skin Cancer Therapy. International Journal of Drug Delivery Technology. 2026;16(32s). doi:10.25258/ijddt.16.32s.7
BibTeX
@article{Solankia2026,
author = {Solankia, Shubham and Kulkarnib, Mangesh and Atarac, Samir},
title = {Formulation and in Vitro Evaluation of Imiquimod-Loaded Zinc Oxide–Mesoporous Silica Hybrid Nanoparticles for Skin Cancer Therapy},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {32s},
doi = {10.25258/ijddt.16.32s.7}
}
EUVIMED